Nu Skin Enterprises (NUS) Misses Q4 EPS by 11c; Guides Well Below the Street

Nu Skin Enterprises (NYSE: NUS) reported Q4 EPS of $0.62, $0.11 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $572.2 million versus the consensus estimate of $585.92 million.

GUIDANCE:

Nu Skin Enterprises sees Q1 2016 EPS of $0.35-$0.38, versus the consensus of $0.73. Nu Skin Enterprises sees Q1 2016 revenue of $450-470 million, versus the consensus of $542.26 million.

Nu Skin Enterprises sees FY2016 EPS of $2.40-$2.60, versus the consensus of $2.89. Nu Skin Enterprises sees FY2016 revenue of $2.1-2.15 billion, versus the consensus of $2.26 billion.

"We generated sequential business improvement in the fourth quarter as we continued introducing our newest ageLOC products," said Truman Hunt, president and chief executive officer. "We began initial sales of our ageLOC Youth nutritional supplement in the Americas region in the fourth quarter, generating a 16 percent year-over-year revenue improvement. This builds on the successful third-quarter introduction of ageLOC Youth in the South Asia/Pacific region.

"The December introduction of our ageLOC Me customized skin care system was well received in Japan where we offered the product only through qualified sales leaders. We were encouraged by product sales, as well as sales leader growth. In South Korea, the introductory offer bundled the ageLOC Me device with a 12-month product subscription commitment. While we believe this approach muted initial sales, we are seeing a high level of follow-on purchases in the first quarter, and we have gained valuable insights from these initial launches that we believe will help us maximize the impact of this innovative product going forward.

"Looking at sales force trends, we see encouraging signs in several markets, which posted sales leader improvements in the quarter," continued Hunt. "As we introduce our new products throughout the year, the key to our success will be our ability to generate growth in sales leaders and a corresponding increase in actives."

For earnings history and earnings-related data on Nu Skin Enterprises (NUS) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Hertz Global (HTZ) Misses Q1 EPS by 83c
• S&P Global (SPGI) Tops Q1 EPS by 36c; offers guidance